Recursion Pharmaceuticals (RXRX) Citi's Biopharma Back to School Conference summary

Technology platform and data integration

• Developed a unified platform with thousands of models, hundreds of algorithms, and 65 petabytes of proprietary data, enabling advanced drug discovery and predictive modeling.

• Focused on integrating diverse data types and experimental validation to ensure model accuracy and robustness.

• Differentiates through proprietary data creation, sophisticated data architecture, and continuous model validation.

• Emphasizes end-to-end capabilities from target identification to clinical trial simulation and patient modeling.

• Open sources select tools to accelerate industry progress, while core value lies in data specificity and model integration.

Partnerships and business model

• Secured nearly $500 million from major partners like Roche and Sanofi, advancing multiple programs and achieving key milestones.

• Partnerships leverage unique technology, such as novel neural cell mapping and advanced chemistry platforms, to solve problems traditional pharma cannot.

• Maintains a risk-diversified model, balancing internal pipeline development with external collaborations.

• Prioritizes deepening existing partnerships while remaining open to new collaborations, with a high bar for resource allocation.

• Avoids SaaS or service-based models in the near term to retain control and address the complexity of drug discovery.

Clinical pipeline and upcoming catalysts

• Pipeline includes four drugs in the clinic, with no single lead program, focusing on high unmet needs and novel biological connections.

• Key programs include a MEK1/2 inhibitor for FAP, CDK7 for oncology, MALT1, and RBM39, each with upcoming data readouts.

• Recent data showed promising results in FAP, including reduction in polyps and dysplasia, with further results expected before year-end.

• CDK7 program demonstrated accurate PK/PD predictions and is advancing to combination studies, targeting a large oncology market.

• RBM39 and MALT1 programs are progressing, with RBM39 showing novel connections not previously documented in literature.